These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 7059416)

  • 21. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM; Chinn LJ; Pedrera HA; Krupnick MI; Suleymanov OD
    J Pharmacol Exp Ther; 1975 Aug; 194(2):450-6. PubMed ID: 1151770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of aldosterone antagonists on mineralocorticoid synthesis in vitro. Inhibition of aldosterone production by prorenoate-K.
    Netchitailo P; Delarue C; Perroteau I; Jegou S; Tonon MC; Leroux P; Leboulenger F; Kusmierek MC; Capron MH; Vaudry H
    Eur J Pharmacol; 1982 Feb; 77(4):243-9. PubMed ID: 6277668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin, diuretics and urinary electrolytes in normal subjects.
    Auty R; Branch RA; Cole EN; Levine D; Ramsay L
    J Endocrinol; 1976 Aug; 70(2):173-81. PubMed ID: 965879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
    Sica DA
    Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
    Casals-Stenzel J; Schmalbach J; Losert W
    Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mineralocorticoid activity and the excretion of an oral potassium load in normal man.
    Hené RJ; Koomans HA; Rabelink AJ; Boer P; Dorhout Mees EJ
    Kidney Int; 1988 Nov; 34(5):697-703. PubMed ID: 3199680
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bioassay of a new aldosterone antagonist and evaluation of a simple method of quantitative comparison.
    McInnes GT; Shelton JR; Asbury MJ; Harrison IR; Clarke JM; Ramsay LE; Venning GR
    Clin Pharmacol Ther; 1981 Aug; 30(2):218-25. PubMed ID: 7249505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activity of sulfur-containing intermediate metabolites of spironolactone.
    McInnes GT; Asbury MJ; Shelton JR; Harrison IR; Ramsay LE; Venning GR; Clarke JM
    Clin Pharmacol Ther; 1980 Mar; 27(3):363-9. PubMed ID: 7357793
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.
    Ramsay LE; Hessian P; Tidd MJ
    Br J Clin Pharmacol; 1975 Jun; 2(3):271-6. PubMed ID: 1234508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the antimineralocorticoid effect of RU 28318 in healthy men with induced exogenous and endogenous hypermineralocorticism.
    Ulmann A; Bertagna C; Le Go A; Husson JM; Tache A; Sassano P; Menard J; Corvol P
    Eur J Clin Pharmacol; 1985; 28(5):531-5. PubMed ID: 3899674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection and comparative evaluation of aldosterone antagonists in glucocorticoid-treated, adrenalectomized rats.
    Casals-Stenzel J; Buse M; Losert W
    Eur J Pharmacol; 1982 May; 80(1):37-45. PubMed ID: 7095004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of aldosterone antagonists in healthy man.
    McInnes GT; Shelton JR; Ramsay LE
    Methods Find Exp Clin Pharmacol; 1982; 4(1):49-71. PubMed ID: 7045549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationships among urinary kallikrein, mineralocorticoids and human hypertensive disease.
    Margolius HS; Horwitz D; Pisano JJ; Keiser HR
    Fed Proc; 1976 Feb; 35(2):203-6. PubMed ID: 1248655
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 35. A comparison of the potassium and magnesium-sparing properties of amiloride and spironolactone in diuretic-treated normal subjects.
    Murdoch DL; Forrest G; Davies DL; McInnes GT
    Br J Clin Pharmacol; 1993 Apr; 35(4):373-8. PubMed ID: 8485017
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites.
    Gardiner P; Schrode K; Quinlan D; Martin BK; Boreham DR; Rogers MS; Stubbs K; Smith M; Karim A
    J Clin Pharmacol; 1989 Apr; 29(4):342-7. PubMed ID: 2723123
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism of action of a new antialdosterone compound, prorenone.
    Claire M; Rafestin-Oblin ME; Michaud A; Roth-Meyer C; Corvol P
    Endocrinology; 1979 Apr; 104(4):1194-200. PubMed ID: 436757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical potassium excretion in response to aldosterone antagonists.
    Ramsay LE; Harrison IR; Shelton JR; Tidd MJ
    Eur J Clin Pharmacol; 1977 Jan; 11(2):101-5. PubMed ID: 837961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of spironolactone treatment on the renin-aldosterone system during pregnancy.
    Lammintausta R; Erkkola R
    Int J Clin Pharmacol Biopharm; 1979 Jul; 17(7):294-8. PubMed ID: 489194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.